Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 2,232 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma, Pancreas Clear all
Suspended Phase 1 Interventional

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

NCT04158635
View directory record Official record
Conditions
Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
Interventions
Bosentan, Gemcitabine, Nab-paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

NCT00005860
View directory record Official record
Conditions
Cancer
Interventions
floxuridine, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 20, 2026, 2:29 PM EDT
Completed No phase listed Observational

A Pilot Study of Diffusion MRI in the Assessment of Pancreatic Tumor Response

NCT01209962
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Not listed
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 20, 2026, 2:29 PM EDT
Terminated Phase 1 Interventional

Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin

NCT01434459
View directory record Official record
Conditions
Pancreatic Neoplasms, Cholangiocarcinoma
Interventions
Gemcitabine with TheraSphere
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 20, 2026, 2:29 PM EDT
Terminated Phase 1 Interventional

Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer

NCT00281996
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Imatinib mesylate
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 26, 2011 · Synced Oct 20, 2026, 2:29 PM EDT
Recruiting Phase 2 Interventional

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

NCT07492680
View directory record Official record
Conditions
Solid Tumors
Interventions
BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig, Pemetrexed, Carboplatin, Nab-paclitaxel, Gemcitabine, Paclitaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
16
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

Pancreatic Adenocarcinoma Signature Stratification for Treatment

NCT04469556
View directory record Official record
Conditions
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Advanced Pancreatic Cancer
Interventions
Folfirinox, Gemcitabine/nab-paclitaxel
Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 20, 2026, 2:29 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus

NCT03937453
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Neoplasms, Diabetes Mellitus
Interventions
MRI/MRCP
Diagnostic Test
Lead sponsor
Nuvance Health
Other
Eligibility
50 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 20, 2026, 2:29 PM EDT
Not yet recruiting Phase 1 Interventional

A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

NCT07650357
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
Interventions
CLSP-5282
Drug
Lead sponsor
Clasp Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Results available

A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer

NCT02237157
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, local delivery
Drug
Lead sponsor
RenovoRx
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Mountain View, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Not applicable Interventional Results available

Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer

NCT01774019
View directory record Official record
Conditions
Pancreatic Carcinoma
Interventions
WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 20, 2026, 2:29 PM EDT
Active, not recruiting Phase 1 Interventional

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

NCT05539430
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
Interventions
LB1908
Biological
Lead sponsor
Legend Biotech USA Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Tampa, Florida • Detroit, Michigan • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 2:29 PM EDT
Recruiting Early Phase 1 Interventional

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

NCT07089940
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Myc Inhibitor OMO-103
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

NCT04902872
View directory record Official record
Conditions
Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma
Interventions
CBX-12
Drug
Lead sponsor
Cybrexa Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
New Haven, Connecticut • Austin, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Phase 3 Interventional Results available

Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas

NCT01438476
View directory record Official record
Conditions
Liver Cancer, Pancreatic Cancer
Interventions
Intravenous Patient-Controlled Analgesia (IVPCA), Thoracic Epidural Analgesia (TEA), Questionnaires, Pain Assessment
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Not applicable Interventional

Supportive Oncology Care at Home for Patients With Pancreatic Cancer Receiving Preoperative FOLFIRINOX

NCT03798769
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Supportive Oncology Care at Home
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 20, 2026, 2:29 PM EDT
Terminated Not applicable Interventional

Nutrition Support to Improve Outcomes in Patients With Unresectable Pancreatic Cancer

NCT02681601
View directory record Official record
Conditions
Cancer of Pancreas
Interventions
Nutrawell Powder, Diet Only, OmegaRich fish oil supplement
Dietary Supplement · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors

NCT00096707
View directory record Official record
Conditions
Lung Cancer, Breast Cancer, Pancreatic Cancer, Head and Neck Cancer, Gastric Cancer
Interventions
2-deoxy-D-glucose (2DG)
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
3
States / cities
Miami, Florida • Indianapolis, Indiana • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Oct 20, 2026, 2:29 PM EDT
Not listed Phase 1 Interventional

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

NCT00986661
View directory record Official record
Conditions
Cancer Metastatic to the Liver, Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Ocular Melanoma, Metastatic Uveal Melanoma, Metastatic Lung Cancer, Metastatic Colon Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer
Interventions
PV-10 (10% rose bengal disodium)
Drug
Lead sponsor
Provectus Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
5
States / cities
San Diego, California • Tampa, Florida • Bethlehem, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 20, 2026, 2:29 PM EDT
Terminated Not applicable Interventional Results available

Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer

NCT01683422
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Proton, Gemcitabine, Erlotinib, Capecitabine, Proton Radiation
Radiation
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

NCT00967577
View directory record Official record
Conditions
Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Esophageal Cancer, Gliomas
Interventions
177Lu-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

NCT06399757
View directory record Official record
Conditions
Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Endometrial Adenocarcinoma, Triple Negative Breast Cancer, Ovarian Cancer, Prostate Cancer
Interventions
APL-5125
Drug
Lead sponsor
Apollo Therapeutics Ltd
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Duarte, California • Irvine, California • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 2:29 PM EDT
Active, not recruiting Phase 3 Interventional

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

NCT07087054
View directory record Official record
Conditions
Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor
Interventions
Paltusotine, Placebo
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
17
States / cities
Gilbert, Arizona • Newport Beach, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

Study of a New Technique for Imaging Pancreatic Cancer

NCT04883775
View directory record Official record
Conditions
Pancreatic Cancer, Tumors That Express CA19-9
Interventions
MVT-2163, MVT-5873
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 20, 2026, 2:29 PM EDT